Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-KRT19 Antibody (6B199) is a Mouse antibody targeting KRT19. Anti-KRT19 Antibody (6B199) can be used in WB,FCM,IP.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $199 | 7-10 days |
Description | Anti-KRT19 Antibody (6B199) is a Mouse antibody targeting KRT19. Anti-KRT19 Antibody (6B199) can be used in WB,FCM,IP. |
Ig Type | Monoclonal Mouse IgG3 |
Clone | 6B199 |
Reactivity | Human |
Verified Activity | 1. KRT19 was immunoprecipitated using: -Lane A:0.5 mg HepG2 Whole Cell Lysate. -4 µL anti-KRT19 mouse monoclonal antibody and 15 μl of 50 % Protein G agarose. -Primary antibody: -Anti-KRT19 mouse monoclonal antibody, at 1:100 dilution. -Secondary antibody: -Dylight 800-labeled antibody to Mouse IgG (H+L), at 1:7500 dilution. -Developed using the odyssey technique. -Performed under reducing conditions. -Predicted band size: 44 kDa. -Observed band size: 40 kDa. 2. Anti-KRT19 mouse monoclonal antibody at 1:500 dilution. -Lane A: HepG2 Whole Cell Lysate. -Lane B: HCT116 Whole Cell Lysate. -Lane C: A431 Whole Cell lysate. -Lysates/proteins at 30 μg per lane. -Secondary -Goat Anti-Mouse IgG H&L (Dylight800) at 1/15000 dilution. -Developed using the Odyssey technique. -Performed under reducing conditions. -Predicted band size:44 kDa. -Observed band size:42 kDa. 3. Flow cytometric analysis of Human KRT19 expression on A431 cells. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human KRT19, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. 4. Anti-KRT19 mouse monoclonal antibody at 1:500 dilution. -Lane A: HepG2 Whole Cell Lysate. -Lane B: KRT19 konckout HepG2 Whole Cell lysate. -Lysates/proteins at 30 μg per lane. -Secondary -Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution. -Developed using the ECL technique. -Performed under reducing conditions. -Predicted band size:44 kDa |
Application | WB,FCM,IP |
Recommended Dose | WB: 1:500-1:2000; FCM: 1:25-1:100; IP: 0.5-2 μL/mg of lysate |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with a synthetic peptide corresponding to the N-terminus of the human KRT19. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Cytokeratin 19 (KRT19) is a cytoplasmic intermediate filament protein, which is responsible for structural rigidity and multipurpose scaffolds. In several cancers, KRT19 is overexpressed and may play a crucial role in tumorigenic transformation. The KRT19 gene encodes cytokeratin 19, an element of the cytoskeleton whose expression is frequently altered in renal cell carcinoma (RCC).KRT19 was identified as one of the key biomarkers for distinguishing cholangiocarcinoma (CCA) and hepatocellular carcinoma. Expression of KRT19 was specifically high in breast cancers and significantly correlated with their invasiveness. Moreover, knockdown of KRT19 led to increased proliferation, migration, invasion, drug resistance, and sphere formation in breast cancer cells via an upregulated NOTCH signaling pathway. |
Conjucates | Unconjugated |
Immunogen | A synthetic peptide corresponding to the N-terminus of the human KRT19 |
Antigen Species | Human |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.